TRVN:OTCMKTS
Trevena Inc
US$0,066
0,00%
(0,00) 1 HR
12 Okt, 14.57.26 GMT-4 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk TRVN...
Kapitalisasi pasar
57,01Â rb
Volume rata-rata
210,00
Volume
16,00
Harga tinggi dalam 52 minggu terakhir
US$1,50
Harga rendah dalam 52 minggu terakhir
US$0,00
Beta
1,07
Saham beredar
864,00Â rb
Jumlah karyawan
23
Kapitalisasi pasar
57,01Â rb
Volume rata-rata
210,00
Volume
16,00
Harga tinggi dalam 52 minggu terakhir
US$1,50
Harga rendah dalam 52 minggu terakhir
US$0,00
Beta
1,07
Saham beredar
864,00Â rb
Jumlah karyawan
23
Artikel berita
Dari sumber web dan partner berita
ad-hoc-news.de
·
22 jam yang lalu
MarketBeat estimates results for Trevena stock
Profil
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Tentang Trevena Inc